Research Article: Impact of wearable device-based interventions with feedback for increasing daily walking activity and physical capacities in cardiovascular patients: a systematic review and meta-analysis of randomised controlled trials
Abstract:
Objective To systematically review randomised controlled trials (RCTs) using a wearable physical activity monitoring device as an intervention to increase daily walking activity and improve physical capacities in patients with cardiovascular disease (CVD). Design Systematic review and meta-analysis of RCTs. Data sources PubMed, Embase and Web of Science from inception to June 2022. Eligibility criteria Randomised controlled studies including patients with CVD over 18 years of age at the end of a cardiac rehabilitation programme comparing an intervention group using a wearable physical activity monitoring device with feedback with usual care or with a control group receiving no feedback on their physical activity and reporting a change in the daily number of steps and/or a change in the distance covered in the 6-minute walk test (6-MWT) or a change in peak oxygen uptake (V?O2 peak ) as endpoints. Results Sixteen RCTs were included. The intervention of wearing a physical activity monitoring device with feedback significantly improved daily number of steps compared with controls (standardised mean difference (SMD) 0.85; 95% CI (0.42; 1.27); p<0.01). The effect was greater when the duration of the intervention was less than 3 months (SMD 1.0; 95% CI (0.18; 1.82); p<0.01) than when the duration of the intervention was 3 months or longer (SMD 0.71; 95% CI (0.27; 1.16); p<0.01), but no significant interaction was found between subgroups (p=0.55). 6-MWT distance and V?O2 peak showed only small effects (SMD 0.34; 95% CI (?0.11; 0.80); p=0.02 and SMD 0.54; 95% CI (0.03; 1.03); p=0.07, respectively). Conclusion The use of wearable physical activity monitoring devices appears to help patients with CVD to increase their daily walking activity and thus their physical activity, particularly in the short term. PROSPERO registration number CRD42022300423.
Introduction:
Cardiovascular diseases (CVDs) remain the leading cause of mortality and disability accounting for approximately 32% of all deaths worldwide 1 and have a significant impact on healthcare costs and systems. Since 2011, physical activity has been recognised as an entire part of therapeutic management in primary, secondary and tertiary prevention; and the benefits of physical activity on morbidity/mortality and health no longer need to be demonstrated. 1–3 The initiation and practice of regular physical activity of…
Read more